Last reviewed · How we verify
NCT04441385: MARACOVID
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
Terminated
Phase 2
Last updated 11 March 2022
What this trial tests
Phase 2 trial testing Maraviroc 300 mg in COVID-19 in 60 participants. Terminated before completion.
Timeline
26 June 2020
Primary endpoint
8 February 2021
8 February 2021
8 February 2021
Quick facts
| Lead sponsor | Hospital Universitario Infanta Leonor |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 26 June 2020 |
| Primary completion | 8 February 2021 |
| Estimated completion | 8 February 2021 |
| Sites | 2 locations across Spain |
Drugs / interventions tested
- Maraviroc 300 mg — full drug profile →
- Standard care therapy
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Hospital Universitario Infanta Leonor
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (COVID-19).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Overview of SARS-CoV-2 infection in adults living with HIV.
Ambrosioni J, Blanco JL, Reyes-Urueña JM, Davies MA, et al · · 2021 · cited 159× · PMID 33915101 · DOI 10.1016/s2352-3018(21)00070-9 -
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895 -
Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.
Al-Horani RA, Kar S. · · 2020 · cited 33× · PMID 32993173 · DOI 10.3390/v12101092 -
Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact.
Zhang S, Asquith B, Szydlo R, Tregoning JS, et al · · 2021 · cited 31× · PMID 35965490 · DOI 10.1093/immadv/ltab015 -
Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19.
Koenig LM, Boehmer DFR, Metzger P, Schnurr M, et al · · 2020 · cited 29× · PMID 32678432 · DOI 10.1084/jem.20201342 -
Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
Files DC, Tacke F, O'Sullivan A, Dorr P, et al · · 2022 · cited 24× · PMID 35749425 · DOI 10.1371/journal.ppat.1010547 -
Repurposing Anti-Cancer Drugs for COVID-19 Treatment.
Borcherding N, Jethava Y, Vikas P. · · 2020 · cited 23× · PMID 33239864 · DOI 10.2147/dddt.s282252 -
The Dual Role of CCR5 in the Course of Influenza Infection: Exploring Treatment Opportunities.
Ferrero MR, Tavares LP, Garcia CC. · · 2021 · cited 22× · PMID 35126379 · DOI 10.3389/fimmu.2021.826621
Verify or expand the search:
- PubMed search for NCT04441385
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Maraviroc 300 mg
Trials testing the same drug.
- NCT05932550 — Safety of Maraviroc for Post-stroke Depression · Phase 2 · completed
- NCT03172026 — Maraviroc to Augment Rehabilitation Outcomes After Stroke · Phase 2, PHASE3 · terminated
- NCT03402815 — Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients. · Phase 4 · completed
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Hospital Universitario Infanta Leonor trials
Trials by the same sponsor.
- NCT05293210 — Early Treatment Strategy With High-dose Dexamethasone in Patients With SARS-CoV-2 · Phase 3 · unknown
- NCT05998499 — HIV-Infected Latin American Asylum Seekers in Europe: Insights From the EuroLatin HIV Cohort · completed
- NCT06189625 — Mild Ankle Sprain Treatment: Functional Bandaging vs. no Immobilization · NA · completed
- NCT04836780 — DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia · Phase 3 · unknown
- NCT04730856 — Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 P · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04441385 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario Infanta Leonor
- Last refreshed: 11 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04441385.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing